0001714899-21-000107.txt : 20211108 0001714899-21-000107.hdr.sgml : 20211108 20211108161617 ACCESSION NUMBER: 0001714899-21-000107 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211104 FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schuth Alexander O. CENTRAL INDEX KEY: 0001724311 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 211388172 MAIL ADDRESS: STREET 1: C/O DENALI THERAPEUTICS INC. STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wf-form4_163640615125307.xml FORM 4 X0306 4 2021-11-04 0 0001714899 Denali Therapeutics Inc. DNLI 0001724311 Schuth Alexander O. C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 COO and Secretary Common Stock 2021-11-04 4 S 0 6717 52.65 D 466366 I See footnote Common Stock 2021-11-04 4 S 0 3283 53.23 D 463083 I See footnote Common Stock 86454 D The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $51.93 to $52.88 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $52.94 to $53.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Includes 75,358 restricted stock units. /s/ Tyler Nielsen, by power of attorney 2021-11-08